Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $5.07 and last traded at $5.03, with a volume of 3355595 shares. The stock had previously closed at $4.82.
Analysts Set New Price Targets
XERS has been the subject of a number of research reports. Craig Hallum raised their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a research note on Friday, March 7th. HC Wainwright restated a "buy" rating and set a $8.00 target price (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Piper Sandler reaffirmed a "neutral" rating and set a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Leerink Partners raised their price target on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a research report on Friday, March 7th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $5.92.
Check Out Our Latest Stock Analysis on Xeris Biopharma
Xeris Biopharma Stock Performance
The stock has a market capitalization of $894.39 million, a P/E ratio of -12.91 and a beta of 2.32. The firm's fifty day simple moving average is $3.83 and its 200 day simple moving average is $3.38.
Hedge Funds Weigh In On Xeris Biopharma
Several hedge funds have recently bought and sold shares of XERS. Connor Clark & Lunn Investment Management Ltd. bought a new position in Xeris Biopharma in the 3rd quarter valued at about $237,000. Intech Investment Management LLC bought a new position in Xeris Biopharma in the 3rd quarter valued at about $130,000. Quantbot Technologies LP bought a new position in Xeris Biopharma in the 3rd quarter valued at about $44,000. Walleye Capital LLC bought a new position in Xeris Biopharma in the 3rd quarter valued at about $3,197,000. Finally, Wellington Management Group LLP boosted its stake in shares of Xeris Biopharma by 11.7% in the 3rd quarter. Wellington Management Group LLP now owns 471,644 shares of the company's stock valued at $1,344,000 after purchasing an additional 49,535 shares in the last quarter. 42.75% of the stock is owned by institutional investors.
Xeris Biopharma Company Profile
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Featured Stories
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
